In this way, preclinical in vivo mouse model studies revealed that intraperitoneally delivered ErbB-targeted CAR T-cells elicited tumor reduction with dose-dependent side effects, whereas when these cells were administered intratumorally or intravenously, there was partial tumor regression with no clinical or histopathological toxicity (176). Here, EGFR is linked to neoplasm.